Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma (Q39137410)

9 September 2017

Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma (English)

1 reference

evasion of host immune response

9 September 2017

1 reference

1 reference

9

Gustav Gaudernack

1 reference

9 September 2017

10

Federico Garrido

1 reference

Gloria González Aseguinolaza

9 September 2017

6

object named as

Gloria González-Aseguinolaza

1 reference

9 September 2017

Ana B del Campo

1

1 reference

9 September 2017

Jon Amund Kyte

2

1 reference

9 September 2017

Javier Carretero

3

1 reference

9 September 2017

Svitlana Zinchencko

4

1 reference

9 September 2017

Rosa Méndez

5

1 reference

9 September 2017

Francisco Ruiz-Cabello

7

1 reference

9 September 2017

Steinar Aamdal

8

1 reference

9 September 2017

Natalia Aptsiauri

11

1 reference

9 September 2017

language of work or name

English

0 references

publication date

16 July 2013

1 reference

International Journal of Cancer

9 September 2017

1 reference

9 September 2017

134

1 reference

9 September 2017

102-113

1 reference

9 September 2017

1

1 reference

Implications for immunosurveillance of altered HLA class I phenotypes in human tumours

9 September 2017

1 reference

MHC class I antigens and immune surveillance in transformed cells.

21 January 2018

1 reference

Mechanisms of immune evasion by tumors

21 January 2018

1 reference

Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma

21 January 2018

1 reference

Human T cell responses against melanoma

21 January 2018

1 reference

Antigen-processing machinery breakdown and tumor growth

21 January 2018

1 reference

Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes

21 January 2018

1 reference

Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations

21 January 2018

1 reference

Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides

21 January 2018

1 reference

The coincidence of chromosome 15 aberrations and beta2-microglobulin gene mutations is causative for the total loss of human leukocyte antigen class I expression in melanoma

21 January 2018

1 reference

Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes

21 January 2018

1 reference

Identification of different tumor escape mechanisms in several metastases from a melanoma patient undergoing immunotherapy

21 January 2018

1 reference

Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy

21 January 2018

1 reference

Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events.

21 January 2018

1 reference

Identification of a lung cancer antigen evading CTL attack due to loss of human leukocyte antigen (HLA) class I expression

21 January 2018

1 reference

Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2-microglobulin loss-of-function in melanoma cells

21 January 2018

1 reference

Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma

21 January 2018

1 reference

A new beta 2 microglobulin mutation found in a melanoma tumor cell line

21 January 2018

1 reference

Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA.

21 January 2018

1 reference

Efficient recovery of HLA class I expression in human tumor cells after beta2-microglobulin gene transfer using adenoviral vector: implications for cancer immunotherapy

21 January 2018

1 reference

Analysis of HLA-ABC locus-specific transcription in normal tissues.

21 January 2018

1 reference

Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy

21 January 2018

1 reference

Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2'-deoxycytidine treatment

21 January 2018

1 reference

Targeting HLA class I expression to increase tumor immunogenicity

21 January 2018

1 reference

Intratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.28338

1 reference

9 September 2017

1 reference